BioAffinity Technologies Secures Patent for Novel Cancer Therapy Targeting CD320 and LRP2 Receptors
On Wednesday, BioAffinity Technologies Inc. (NASDAQ:BIAF) announced that the US Patent and Trademark Office/USPTO has issued a new patent. The patent is titled "Compositions and Methods for Treating Cancer," and covers a novel method and composition for selectively eliminating cancer cells by targeting the CD320 and LRP2 receptors on the cell membrane.
The therapeutic approach outlined in the patent applies to a broad spectrum of cancers, including those of the lung, breast, prostate, brain, and skin. BioAffinity Technologies has already initiated research towards developing a topical treatment for skin cancers. The new patent supports the company's intellectual property portfolio, which now includes 19 awarded US and foreign patents and 36 pending patent applications related to its diagnostic platform and cancer treatment therapeutics.
A medical professional in a hospital, using targeted cancer therapuetics to treat cancer patients.
The invention utilizes small interfering RNAs (siRNAs) to suppress the expression of CD320 and LRP2 proteins. In vitro studies have demonstrated that the simultaneous knockdown of both proteins is selectively cytotoxic to human cancer cells, while sparing normal cells under the same treatment conditions. The studies also indicated that the double knockdown of CD320 and LRP2 is crucial, as down-regulating only one receptor led to increased protein expression in the other, and was insufficient to kill cancer cells or significantly inhibit their proliferation.
BioAffinity Technologies Inc. (NASDAQ:BIAF) develops non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the US. It operates through two segments: Diagnostic R&D and Laboratory Services.
While we acknowledge the potential of BIAF to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BIAF and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: and .
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Musk-Trump Space Showdown Sends Rocket Lab Shares Soaring
June 9 - Rocket Lab USA Inc (NASDAQ:RKLB) shares climbed about 8% on Monday as investors reacted to a weekend spat between SpaceX CEO Elon Musk and former President Donald Trump. The feud began when Musk criticized Trump's proposed tax legislation on X, prompting Trump to suggest cutting Musk's government contracts. Musk fired back, hinting he might decommission SpaceX's Dragon spacecraft, currently the only U.S. vehicle for ferrying astronauts to the International Space Station, before retracting the comment. Over the weekend, Musk posted that we have got the spaceships, and they do not, implying U.S. reliance on SpaceX. That argument appears to be fueling interest in rival aerospace firms. RKLB, which holds multiple NASA contracts and is viewed as a contender for Trump's $175 billion Golden Dome missile defense initiative, saw its stock hit $31.21 in morning trading. AST SpaceMobile Inc (NASDAQ:ASTS) shares surged about 17% after reports suggested U.S. policymakers may look beyond SpaceX for various space investments. ASTS, a top customer of Blue Origin, inked a November launch deal with Jeff Bezos' company to deploy up to 45 satellites. Both RKLB and ASTS traded on above-average volume, signaling heightened investor focus on alternative space players amid the high-profile Musk-Trump clash. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Are Companies About to Dump Their Bitcoin? The Warning Signs Are Here
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. The cryptocurrency landscape has witnessed a significant shift as corporations increasingly adopt bitcoin as a treasury asset. While this trend has contributed to bitcoin's recent price surge, it may also be creating new vulnerabilities in the market that warrant careful consideration. Corporate adoption of bitcoin has accelerated notably, with companies following the playbook pioneered by MicroStrategy (NASDAQ:MSTR). According to Bitcoin Treasuries data, 110 publicly listed companies globally now hold bitcoin, representing a substantial institutional commitment to the digital asset. Don't Miss: — no wallets, just price speculation and free paper trading to practice different strategies. Grow your IRA or 401(k) with Crypto – . Standard Chartered's analysis focuses on a refined sample of 61 companies that purchase bitcoin purely as a treasury holding, excluding industry participants like miners, exchanges, and service providers. This subset collectively owned nearly 674,000 bitcoins as of May's end—representing 3.2% of bitcoin's total 21 million coin supply. The numbers tell a compelling story: these 'bitcoin treasuries' have doubled their holdings over just two months, accumulating close to 100,000 additional bitcoins during this period. This buying pressure has been a key factor driving bitcoin to recent all-time highs. However, Standard Chartered's analysis reveals a concerning dynamic that could eventually reverse this supportive trend. Unlike Strategy, which accumulated bitcoin over time at various price points, many newer corporate entrants have purchased at significantly higher average prices. The bank's research suggests that approximately half of the monitored corporate treasuries would find themselves underwater if bitcoin fell below $90,000. This creates a potential domino effect where companies that entered the bitcoin treasury strategy during price peaks could become forced sellers during market downturns. The risk stems from several interconnected factors: Purchase Price Disparities: Most corporate treasuries in Standard Chartered's sample have average purchase prices well above Strategy's cost basis, making them more vulnerable to market volatility. NAV Multiple Justification: Currently, companies holding bitcoin trade at Net Asset Value multiples above 1, justified by market inefficiencies such as regulatory constraints and conservative institutional investment processes. As these barriers diminish over time, the premium valuations may compress. Corporate Pain Thresholds: Unlike dedicated cryptocurrency companies, traditional corporations may have lower tolerance for significant losses on treasury holdings. Standard Chartered estimates that newer entrants likely couldn't withstand a 50% decline from their average purchase price—a threshold that Strategy weathered during the 2022 crypto winter. Trending: New to crypto? on Coinbase. The analysis suggests that if bitcoin drops more than 22% below companies' average purchase prices, forced selling could emerge. This creates a feedback loop where price declines trigger corporate selling, potentially accelerating further declines. This dynamic differs markedly from Strategy's experience in November 2022, when bitcoin halved but the company maintained its position. Several factors may have aided Strategy's resilience: smaller absolute dollar losses at the time, the absence of U.S. spot bitcoin ETFs providing alternative exposure, and the company's fundamental commitment to bitcoin as a long-term strategy. This corporate treasury trend presents both opportunities and risks for the broader bitcoin market: Positive Factors: Corporate adoption provides institutional legitimacy and substantial buying pressure that has supported recent price appreciation. Risk Factors: The concentration of recent purchases at higher price levels creates potential selling pressure during market stress, possibly amplifying volatility. Timing Considerations: As market inefficiencies that currently justify premium valuations are resolved, bitcoin treasuries could shift from price supporters to sources of downside pressure. While corporate bitcoin adoption represents a significant maturation of the cryptocurrency market, investors should recognize that these treasury strategies may behave differently than those of dedicated bitcoin companies during market stress. The sustainability of this trend will likely depend on bitcoin's price stability and these companies' ability to maintain their positions through potential volatility. As Standard Chartered notes, the question isn't whether these companies will face pressure, but rather how much volatility they can withstand before strategic considerations shift. For market participants, understanding these dynamics becomes crucial as corporate treasuries represent an increasingly significant portion of bitcoin's circulating supply. Their behavior during the next major market downturn will provide important insights into the resilience of this newer form of institutional bitcoin adoption. Read Next: A must-have for all crypto enthusiasts: . Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Image: Shutterstock This article Are Companies About to Dump Their Bitcoin? The Warning Signs Are Here originally appeared on
Yahoo
28 minutes ago
- Yahoo
Sharps Technology CEO, Robert Hayes, to Present at the Virtual Investor Summit on June 10, 2025
Presentation to be webcast live at 10:00 AM ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (Nasdaq: 'STSS' and 'STSSW') ('Sharps'), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart safety syringe products to the healthcare industry, today announced that Robert Hayes, CEO, will present at the Virtual Investor Summit on June 10, 2025, at 10:00 AM ET. Investors are invited to listen to the presentation and can register here. Sharps recently announced that the Company has commenced shipments under three customer orders tied to previously announced purchase agreements. These shipments represent the Company's first commercial deliveries and its transition to revenue-generating operations. All products are being manufactured and shipped from Sharps' facility in Hungary, which has undergone significant upgrades to support high-volume production. Read the update release HERE. Presentation Details: Event: Q2 Investor Summit Date & Time: 10:00 AM ET on June 10, 2025 Presenter: Robert Hayes, CEO Webcast: LINK HERE Conference Overview and Structure:The Investor Summit is an exclusive event tailored for investors focused on small- and micro-cap stocks. It offers a unique opportunity to meet with management teams from high-potential emerging companies, gain insights from industry experts, and understand how peers are navigating the current market environment. This quarter's event centers on micro-cap companies that are currently undervalued and positioned near catalyst events that could significantly accelerate their growth trajectory. Registration for Investors:To request free registration, please go to the Investor Summit website, ( and click the "Registration" button. For More Information, please visit: or, contact johnna-mae@ About Sharps Technology:Sharps Technology is an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry. The Company's product lines focus on providing ultra-low waste capabilities, that incorporate syringe technologies that use both passive and active safety features. Sharps also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. The Company has a manufacturing facility in Hungary. For additional information, please visit FORWARD-LOOKING STATEMENTS:This press release contains 'forward-looking statements'. Forward-looking statements reflect our current view about future events. When used in this press release, the words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'future,' 'intend,' 'plan,' 'poised' or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity, and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance, or achievements. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Investor Contact:Holdsworth PartnersAdam HoldsworthPhone: 917-497-9287Email: IR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
